Clinical Research Details

Back to List
Descriptive Information
Neurocognitive Markers of SSRI Treatment Response in Pediatric Depression

Fadi T Maalouf
fm38@aub.edu.lb

PSY.FM.02
Completed- Has Results

Clinical Research - Epidemiologic and Behavioral Studies  


No
Coordinators
Farah Tabaja
fat01@mail.aub.edu
Conditions and Keywords
Depression
Depression ,SSRI ,Neurocognitive markers
Study Design
Treatment
N/A: Not Applicable
Prospective
N/A: Not Applicable
Parallel
N/A: Not Applicable
Case Control
Eligibility and IRB
Both
Min: 12
Max: 18
Yes
Yes

The study aims to investigate the changes in neurocognitive functioning in adolescents with MDD during an acute treatment course with SSRI. 24 adolescents with current Major Depression (MDD) and 24 Healthy Controls (HC) were administered subtests of the Cambridge Neuropsychological Test Automated Battery (CANTAB) as well as clinical scales at baseline and were rested at weeks 6 and 12. MDD were started on Fluoxetine after baseline assessment.

Adolescents with major depressive disorder vs healthy adolescents
MDD patients were recruited from Child and Adolescent Psychiatry clinic at AUBMC, healthy controls were recruited from Family Medicine clinic at AUBMC.

-Ages 12-18

-Meet criteria for Major Depressive Disorder

-Obtain score higher than 40 on the Childhood Depression Rating Scale (Revised)

-Healthy controls must have no previous psychiatric history and no previous psychiatric disorders in first degree relatives.


Back to List